Regeneron Pharmaceuticals Stock Performance
| REGN Stock | USD 893.99 7.20 0.80% |
The company holds a Beta of 0.83, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Regeneron Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Regeneron Pharmaceuticals is expected to be smaller as well. Regeneron Pharmaceuticals has an expected return of -0.057%. Please make sure to check Regeneron Pharmaceuticals value at risk, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Regeneron Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Regeneron Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy technical and fundamental indicators, Regeneron Pharmaceuticals is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 0.79 | Five Day Return (1.14) | Year To Date Return (0.42) | Ten Year Return 198.41 | All Time Return 4.2 K |
1 | Disposition of tradable shares by Arthur Ryan of Regeneron Pharmaceuticals at 986.58 subject to Rule 16b-3 | 03/18/2024 |
2 | Non-melanoma Skin Cancer Market to Hit US 8,859.6 Million by 2034 Fact.MR Report | 03/20/2024 |
3 | Disposition of tradable shares by Andrew Murphy of Regeneron Pharmaceuticals at 962.87 subject to Rule 16b-3 | 03/22/2024 |
4 | FDA issues response letters for Regenerons cancer drug | 03/25/2024 |
5 | Aardvark Therapeutics gearing up for 200 million IPO | 04/01/2024 |
6 | Global Biobetters Market Analysis to 2034 by Drug Class, Disease Indication, Route of Administration, Distribution Channel, and Region, Featuring Exhaustive Pro... | 04/09/2024 |
7 | Is There An Opportunity With Regeneron Pharmaceuticals, Inc.s 47 percent Undervaluation | 04/10/2024 |
8 | Are Regenerons Legal Troubles And Six-Week Slide A Buying Opportunity | 04/11/2024 |
9 | Food Allergy Pipeline Landscape Research Report 2024 Comprehensive Insights About 30 Companies and 35 Pipeline Drugs | 04/12/2024 |
10 | Regeneron to defend against DOJ complaint on drug-price manipulation | 04/15/2024 |
11 | AmgenAstraZenecas Asthma Drug Tezspire Vs. SanofiRegenerons Blockbuster Dupixent - Analyst Gives His Pick | 04/17/2024 |
| Begin Period Cash Flow | 3.1 B |
Regeneron |
Regeneron Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 93,340 in Regeneron Pharmaceuticals on January 19, 2024 and sell it today you would lose (3,526) from holding Regeneron Pharmaceuticals or give up 3.78% of portfolio value over 90 days. Regeneron Pharmaceuticals is currently does not generate positive expected returns and assumes 0.9139% risk (volatility on return distribution) over the 90 days horizon. In different words, 8% of stocks are less volatile than Regeneron, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Regeneron Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Regeneron Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Regeneron Pharmaceuticals, and traders can use it to determine the average amount a Regeneron Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0624
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | REGN |
Estimated Market Risk
| 0.91 actual daily | 8 92% of assets are more volatile |
Expected Return
| -0.06 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Regeneron Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Regeneron Pharmaceuticals by adding Regeneron Pharmaceuticals to a well-diversified portfolio.
Regeneron Pharmaceuticals Fundamentals Growth
Regeneron Stock prices reflect investors' perceptions of the future prospects and financial health of Regeneron Pharmaceuticals, and Regeneron Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Regeneron Stock performance.
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.0849 | ||||
| Profit Margin | 0.30 % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 88.03 B | ||||
| Shares Outstanding | 107.94 M | ||||
| Price To Earning | 15.51 X | ||||
| Price To Book | 3.82 X | ||||
| Price To Sales | 7.57 X | ||||
| Revenue | 13.12 B | ||||
| Gross Profit | 7.02 B | ||||
| EBITDA | 4.05 B | ||||
| Net Income | 3.95 B | ||||
| Cash And Equivalents | 7.02 B | ||||
| Cash Per Share | 65.75 X | ||||
| Total Debt | 2.7 B | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 5.36 X | ||||
| Book Value Per Share | 242.47 X | ||||
| Cash Flow From Operations | 4.59 B | ||||
| Earnings Per Share | 34.78 X | ||||
| Market Capitalization | 98.14 B | ||||
| Total Asset | 33.08 B | ||||
| Retained Earnings | 27.26 B | ||||
| Working Capital | 16.06 B | ||||
| Current Asset | 2.92 B | ||||
| Current Liabilities | 811.16 M | ||||
About Regeneron Pharmaceuticals Performance
To evaluate Regeneron Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Regeneron Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Regeneron Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Regeneron Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Regeneron's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 518.71 | 544.65 | |
| Return On Tangible Assets | 0.12 | 0.13 | |
| Return On Capital Employed | 0.14 | 0.14 | |
| Return On Assets | 0.12 | 0.13 | |
| Return On Equity | 0.15 | 0.16 |
Things to note about Regeneron Pharmaceuticals performance evaluation
Checking the ongoing alerts about Regeneron Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Regeneron Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Regeneron Pharmaceuticals generated a negative expected return over the last 90 days | |
| Regeneron Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| Over 89.0% of the company shares are owned by institutional investors | |
| Latest headline from benzinga.com: AmgenAstraZenecas Asthma Drug Tezspire Vs. SanofiRegenerons Blockbuster Dupixent - Analyst Gives His Pick |
- Analyzing Regeneron Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Regeneron Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Regeneron Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Regeneron Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Regeneron Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Regeneron Pharmaceuticals' stock. These opinions can provide insight into Regeneron Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for Regeneron Stock analysis
When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.03) | Earnings Share 34.78 | Revenue Per Share 122.935 | Quarterly Revenue Growth 0.006 | Return On Assets 0.0849 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.